An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications about 58% were on their treatment plan for less than 12 weeks, falling short of a key benchmark in the weight-loss treatment timeline
(source: prnewswire.com) GLP-1 Analogues Market Segmentation By Route of Administration Outlook Subcutaneous Route Oral Route By Product Outlook Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Victoza Zepbound Other Products By Application Outlook Type 2 Diabetes Mellitus Obesity Others Applications By Distribution Channel Outlook Hospital Pharmacies Retail Pharmacies Online Pharmacies By Regional Outlook North America US Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Analogues Market Report Scope Source: Polaris Market Research Analysis GLP-1 Analogues Market FAQ's The global GLP-1 analogues market size was valued at USD 56.62 billion in 2025
For women interested in a comprehensive approach, combining GLP-1 therapy with hormone optimization may offer additional support for managing midlife metabolic changes
Worldwide agencies, such as the European Medicines Agency or Japans PMDA, have their own standards, and all must be satisfied before retatrutide can be marketed in those nations
Focus on the Positives While weight loss is a primary goal, shift focus beyond just the number on the scale
Based on conversations with Lamya Kamal, a Dubai-based family medicine specialist and Zeenat Naseeb Abdul Wahid, Consultant Endocrinology, Medcare Hospital Sharjah, Hala Zakaria, Researcher at Zone Health and Nas Al Jafari, a Dubai-based functional medicinal specialist at DNA Health Clinic, we break it down
